KTTA
Pasithea Therapeutics Corp.
Biotechnology
Market Cap$18M
5Y Perf.-98.7%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
KTTA vs CYBN vs CMPS vs MNMD
Revenue, margins, valuation, and 5-year total return — side by side.
CYBN
Cybin Inc.
Biotechnology
Market Cap$304M
5Y Perf.-92.0%
CMPS
COMPASS Pathways plc
Medical - Care Facilities
Market Cap$952M
5Y Perf.-66.8%
MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.-45.9%
KTTA vs CYBN vs CMPS vs MNMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KTTA | CYBN | CMPS | MNMD |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Medical - Care Facilities | Biotechnology |
| Market Cap | $18M | $304M | $952M | $2.04B |
| Revenue (TTM) | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income (TTM) | $-13M | $-123M | $-288M | $-238M |
| Total Debt | $0.00 | $0.00 | $21M | $0.00 |
| Cash & Equiv. | $7M | $135M | $150M | $258M |
KTTA vs CYBN vs CMPS vs MNMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KTTA
CYBN
CMPS
MNMD
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Pasithea Therapeuti… (KTTA) | 100 | 1.3 | -98.7% |
| Cybin Inc. (CYBN) | 100 | 8.0 | -92.0% |
| COMPASS Pathways plc (CMPS) | 100 | 33.2 | -66.8% |
| Mind Medicine (Mind… (MNMD) | 100 | 54.1 | -45.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KTTA vs CYBN vs CMPS vs MNMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KTTA and CYBN are tied at the top with 2 categories each — the right choice depends on your priorities. Cybin Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. MNMD also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
KTTA
Pasithea Therapeutics Corp.
The Income Pick
KTTA carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.12
- Lower volatility, beta 1.12, current ratio 6.58x
- Beta 1.12, current ratio 6.58x
- 15.2% revenue growth vs MNMD's -96.9%
Best for: income & stability and sleep-well-at-night
CYBN
Cybin Inc.
The Growth Play
CYBN is the #2 pick in this set and the best alternative if growth exposure is your priority.
- EPS growth 93.5%
- 3.2% margin vs MNMD's 1.2%
- -58.3% ROA vs CMPS's -106.8%
Best for: growth exposure
CMPS
COMPASS Pathways plc
The Secondary Option
CMPS lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
MNMD
Mind Medicine (MindMed) Inc.
The Long-Run Compounder
MNMD is the clearest fit if your priority is long-term compounding.
- 5.1% 10Y total return vs CMPS's -65.8%
- +220.3% vs KTTA's -17.2%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KTTA | 15.2% revenue growth vs MNMD's -96.9% |
| Quality / Margins | CYBN | 3.2% margin vs MNMD's 1.2% |
| Stability / Safety | KTTA | Beta 1.12 vs MNMD's 1.63 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | MNMD | +220.3% vs KTTA's -17.2% |
| Efficiency (ROA) | CYBN | -58.3% ROA vs CMPS's -106.8% |
KTTA vs CYBN vs CMPS vs MNMD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKTTALAGGINGCMPS
Who Leads Where
KTTA leads in 1 of 6 categories
MNMD leads 1 • CYBN leads 0 • CMPS leads 0 • 3 tied
Explore the data ↓CMPSCOMPASS Pathways plc
0leads
CYBNCybin Inc.
0leads
MNMDMind Medicine (MindMe…
1leads
KTTAPasithea Therapeutics…
1leads
6 Total Categories
CATEGORYLEADERvs MNMDvs CYBNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KTTA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
MNMD6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KTTA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
KTTA and MNMD operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | KTTAPasithea Therapeu… | CYBNCybin Inc. | CMPSCOMPASS Pathways … | MNMDMind Medicine (Mi… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $0 | $0 |
| EBITDAEarnings before interest/tax | -$13M | -$147M | -$179M | -$191M |
| Net IncomeAfter-tax profit | -$13M | -$123M | -$288M | -$238M |
| Free Cash FlowCash after capex | -$12M | -$106M | -$157M | -$174M |
| Gross MarginGross profit ÷ Revenue | — | — | — | — |
| Operating MarginEBIT ÷ Revenue | — | — | — | — |
| Net MarginNet income ÷ Revenue | — | — | — | — |
| FCF MarginFCF ÷ Revenue | — | — | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +85.7% | -8.2% | -58.7% | -163.0% |
KTTA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — KTTA and CYBN each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | KTTAPasithea Therapeu… | CYBNCybin Inc. | CMPSCOMPASS Pathways … | MNMDMind Medicine (Mi… |
|---|---|---|---|---|
| Market CapShares × price | $18M | $304M | $952M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $11M | $205M | $824M | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.06x | -13.66x | -3.22x | -10.04x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — | — | — |
| Price / BookPrice ÷ Book value/share | 0.06x | 6.52x | — | 5.56x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Evenly matched — KTTA and CYBN each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — CYBN and MNMD each lead in 5 of 8 comparable metrics.
Profitability & Efficiency
CYBN delivers a -81.0% return on equity — every $100 of shareholder capital generates $-81 in annual profit, vs $-3 for CMPS. On the Piotroski fundamental quality scale (0–9), CYBN scores 3/9 vs CMPS's 2/9, reflecting mixed financial health.
| Metric | KTTAPasithea Therapeu… | CYBNCybin Inc. | CMPSCOMPASS Pathways … | MNMDMind Medicine (Mi… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -97.9% | -81.0% | -3.4% | -102.5% |
| ROA (TTM)Return on assets | -88.0% | -58.3% | -106.8% | -70.7% |
| ROICReturn on invested capital | -142.4% | -115.8% | — | -3.9% |
| ROCEReturn on capital employed | -74.2% | -54.1% | -2.5% | -52.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 | 2 | 3 |
| Debt / EquityFinancial leverage | — | — | — | — |
| Net DebtTotal debt minus cash | -$7M | -$135M | -$129M | -$258M |
| Cash & Equiv.Liquid assets | $7M | $135M | $150M | $258M |
| Total DebtShort + long-term debt | $0 | $0 | $21M | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | — | -52.40x | -21.81x |
Evenly matched — CYBN and MNMD each lead in 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNMD five years ago would be worth $4,493 today (with dividends reinvested), compared to $112 for KTTA. Over the past 12 months, MNMD leads with a +220.3% total return vs KTTA's -17.2%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs KTTA's -51.8% — a key indicator of consistent wealth creation.
| Metric | KTTAPasithea Therapeu… | CYBNCybin Inc. | CMPSCOMPASS Pathways … | MNMDMind Medicine (Mi… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -33.2% | -26.4% | +51.3% | +51.7% |
| 1-Year ReturnPast 12 months | -17.2% | -8.1% | +163.6% | +220.3% |
| 3-Year ReturnCumulative with dividends | -88.8% | -49.8% | +17.1% | +510.3% |
| 5-Year ReturnCumulative with dividends | -98.9% | -90.2% | -72.3% | -55.1% |
| 10-Year ReturnCumulative with dividends | -98.9% | -99.7% | -65.8% | +512.1% |
| CAGR (3Y)Annualised 3-year return | -51.8% | -20.5% | +5.4% | +82.7% |
MNMD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KTTA and MNMD each lead in 1 of 2 comparable metrics.
Risk & Volatility
KTTA is the less volatile stock with a 1.12 beta — it tends to amplify market swings less than MNMD's 1.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs KTTA's 38.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KTTAPasithea Therapeu… | CYBNCybin Inc. | CMPSCOMPASS Pathways … | MNMDMind Medicine (Mi… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.12x | 1.49x | 1.28x | 1.63x |
| 52-Week HighHighest price in past year | $2.06 | $9.83 | $10.21 | $21.09 |
| 52-Week LowLowest price in past year | $0.28 | $5.50 | $2.25 | $6.03 |
| % of 52W HighCurrent price vs 52-week peak | +38.6% | +62.0% | +97.1% | +98.1% |
| RSI (14)Momentum oscillator 0–100 | 61.5 | 35.5 | 63.4 | 64.9 |
| Avg Volume (50D)Average daily shares traded | 459K | 292K | 3.6M | 779K |
Evenly matched — KTTA and MNMD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: CYBN as "Buy", CMPS as "Buy", MNMD as "Buy". Consensus price targets imply 81.6% upside for CMPS (target: $18) vs -3.3% for MNMD (target: $20).
| Metric | KTTAPasithea Therapeu… | CYBNCybin Inc. | CMPSCOMPASS Pathways … | MNMDMind Medicine (Mi… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $18.00 | $20.00 |
| # AnalystsCovering analysts | — | 4 | 13 | 1 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KTTA leads in 1 of 6 categories (Income & Cash Flow). MNMD leads in 1 (Total Returns). 3 tied.
Best OverallPasithea Therapeutics Corp. (KTTA)Leads 1 of 6 categories
Loading custom metrics...
KTTA vs CYBN vs CMPS vs MNMD: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is KTTA or CYBN or CMPS or MNMD a better buy right now?
Analysts rate Cybin Inc.
(CYBN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KTTA or CYBN or CMPS or MNMD?
Over the past 5 years, Mind Medicine (MindMed) Inc.
(MNMD) delivered a total return of -55. 1%, compared to -98. 9% for Pasithea Therapeutics Corp. (KTTA). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus CYBN's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KTTA or CYBN or CMPS or MNMD?
By beta (market sensitivity over 5 years), Pasithea Therapeutics Corp.
(KTTA) is the lower-risk stock at 1. 12β versus Mind Medicine (MindMed) Inc. 's 1. 63β — meaning MNMD is approximately 45% more volatile than KTTA relative to the S&P 500.
04Which is growing faster — KTTA or CYBN or CMPS or MNMD?
On earnings-per-share growth, the picture is similar: Cybin Inc.
grew EPS 93. 5% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KTTA or CYBN or CMPS or MNMD?
Pasithea Therapeutics Corp.
(KTTA) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Mind Medicine (MindMed) Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KTTA leads at 0. 0% versus 0. 0% for MNMD. At the gross margin level — before operating expenses — KTTA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — KTTA or CYBN or CMPS or MNMD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is KTTA or CYBN or CMPS or MNMD better for a retirement portfolio?
For long-horizon retirement investors, Pasithea Therapeutics Corp.
(KTTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 12)). Both have compounded well over 10 years (KTTA: -98. 9%, CYBN: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between KTTA and CYBN and CMPS and MNMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.